Literature DB >> 20047763

Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutinin.

Jonathan W Yewdell1.   

Abstract

Antibodies (Abs) specific for the globular domain of influenza A virus hemagglutinin (HA) efficiently neutralize viral infectivity and provide the most effective protection against influenza following infection or vaccination. Nearly all neutralizing Abs recognize discontinuous determinants formed by residues present on different stretches of the HA primary structure. Here, I show that approximately 25% of a large panel of neutralizing monoclonal Abs (mAbs), including Abs specific for each of the four major antigenic sites, can bind to completely denatured HA. Binding of these mAbs to denatured HA occurs much more slowly than binding to native HA, but bound mAbs dissociate from denatured and native HA with similar kinetics, and amino acid substitutions that reduce mAb binding to native HA have a similar effect on mAb interaction with denatured HA. HA refolding induced by mAb binding facilitated the binding of mAbs to other antigenic sites, indicating that refolding was not limited to the antibody-interaction domain. These findings validate the localization of antigenic sites by identifying amino acid substitutions selected in mAb escape mutants. Further, they demonstrate that Abs can facilitate the refolding of denatured proteins, which suggests a number of practical applications for optimizing antibody based assays, and also for potentially using Abs as specific chaperones for protein refolding. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047763      PMCID: PMC2814887          DOI: 10.1016/j.molimm.2009.10.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  23 in total

Review 1.  The role of the antibody response in influenza virus infection.

Authors:  W Gerhard
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  The structure and receptor binding properties of the 1918 influenza hemagglutinin.

Authors:  S J Gamblin; L F Haire; R J Russell; D J Stevens; B Xiao; Y Ha; N Vasisht; D A Steinhauer; R S Daniels; A Elliot; D C Wiley; J J Skehel
Journal:  Science       Date:  2004-02-05       Impact factor: 47.728

3.  Mutations in or near the fusion peptide of the influenza virus hemagglutinin affect an antigenic site in the globular region.

Authors:  J W Yewdell; A Taylor; A Yellen; A Caton; W Gerhard; T Bächi
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

Review 4.  Structural basis of immune recognition of influenza virus hemagglutinin.

Authors:  I A Wilson; N J Cox
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

5.  Antigenicity of polypeptides (poly alpha amino acids): calcium-dependent and independent antibodies.

Authors:  P H Maurer; L G Clark; P A Liberti
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

6.  The activation of mutant beta-galactosidase by specific antibodies. Purification of eleven antibody activatable mutant proteins and their subunits on sepharose immunosorbents. Determination of the molecular weights by sedimentation analysis and acrylamide gel electrophoresis.

Authors:  F Melchers; W Messer
Journal:  Eur J Biochem       Date:  1970-12

Review 7.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

Authors:  J J Skehel; D C Wiley
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 8.  Filamentous fusion phage cloning vectors for the study of epitopes and design of vaccines.

Authors:  S F Parmley; G P Smith
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

Review 9.  Variation and infectivity neutralization in influenza.

Authors:  Marcel Knossow; John J Skehel
Journal:  Immunology       Date:  2006-09       Impact factor: 7.397

10.  Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act.

Authors:  Anthony S Fauci
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

View more
  7 in total

1.  Influenza A virus hemagglutinin trimerization completes monomer folding and antigenicity.

Authors:  Javier G Magadán; Surender Khurana; Suman R Das; Gregory M Frank; James Stevens; Hana Golding; Jack R Bennink; Jonathan W Yewdell
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

2.  Monitoring cotranslational protein folding in mammalian cells at codon resolution.

Authors:  Yan Han; Alexandre David; Botao Liu; Javier G Magadán; Jack R Bennink; Jonathan W Yewdell; Shu-Bing Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

3.  Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.

Authors:  Kari Debbink; Eric F Donaldson; Lisa C Lindesmith; Ralph S Baric
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

4.  Viewing folding of nascent polypeptide chains from ribosomes.

Authors:  Botao Liu; Crystal S Conn; Shu-Bing Qian
Journal:  Expert Rev Proteomics       Date:  2012-12       Impact factor: 3.940

5.  High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.

Authors:  Kelvin K W To; Anna J X Zhang; Ivan F N Hung; Ting Xu; Whitney C T Ip; Rebecca T Y Wong; Joseph C K Ng; Jasper F W Chan; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2012-05-09

6.  Complete Protection against Influenza Virus H1N1 Strain A/PR/8/34 Challenge in Mice Immunized with Non-Adjuvanted Novirhabdovirus Vaccines.

Authors:  Ronan N Rouxel; Emilie Mérour; Stéphane Biacchesi; Michel Brémont
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

7.  Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs.

Authors:  Ivan Kosik; William L Ince; Lauren E Gentles; Andrew J Oler; Martina Kosikova; Matthew Angel; Javier G Magadán; Hang Xie; Christopher B Brooke; Jonathan W Yewdell
Journal:  PLoS Pathog       Date:  2018-01-18       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.